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thromboembolic events have been reported with C1-INH use, generally off-label and at supratherapeutic doses.
What does this article add to our knowledge? This large, international, registry of patients using C1-INH is the most
extensive of its kind, providing real-world data regarding general safety and intentional surveillance for issues of particular
interest, including thromboembolism and possible viral transmission.
How does this study impact current management guidelines? Recent HAE guidelines consistently recommend self-
administration of C1-INH. The Berinert registry data provide real-world evidence for widespread implementation of this
practice and support the feasibility and safety of C1-INH administration outside of a health care setting.BACKGROUND: The plasma-derived, highly puriﬁed, nano-
ﬁltered C1-inhibitor concentrate (Berinert; “pnfC1-INH”) is
approved in the United States for treating hereditary angioe-
dema (HAE) attacks and in many European countries for attack
treatment and short-term prophylaxis.
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cases associated with factor XII activation mutations.2 Clinically,
HAE is characterized by episodes of localized subcutaneous or
submucosal swelling usually involving the skin (without urti-
caria), upper airways, and gastrointestinal and urogenital tracts.1
Laryngeal edema is the least frequent type of attack, but is
potentially life threatening if not properly treated.3,4
Recommended strategies for HAE management include access
to on-demand treatment of HAE attacks for all patients, short-
term prophylaxis for patients anticipating events that might
trigger an HAE attack, and long-term prophylaxis in appropriate
patients.5-10 There is an increasing trend toward patient-
administered HAE therapy outside of a health care setting (ie,
caregiver- or self-administration),1,5,6,8-14 an approach that offers
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suggested that more than two-thirds of patients using C1-INH
were being infused at home.16
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TABLE I. Registry population demographics (subjects who
received at least 1 administration of pnfC1-INH)
Safety population Total N [ 318
Sex, n (%)
Male 111 (34.9)
Female 207 (65.1)
Race, n (%)
Asian 2 (0.6)
Black/African American 8 (2.5)
White 298 (93.7)
Other 9 (2.8)
Missing 1 (0.3)
Age (y)
Mean (SD) 38.8 (17.92)
Range 5-83
pnfC1-INH, Plasma-derived, highly puriﬁed, pasteurized, nanoﬁltered C1-inhibitor
concentrate; SD, standard deviation.
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and efﬁcacy proﬁle, with more than 35 years of availability in
Europe.17
The Berinert Patient Registry (hereafter, “Registry”) was
created to evaluate the safety of pnfC1-INH in a “real-world”
setting and to gather more information on usage patterns for
pnfC1-INH. Information on thromboembolic events (TEEs)
was a particular focus of the Registry, given previously reported
events in patients treated with plasma-derived C1-INH,18-20 in
many cases for unapproved uses and/or at supratherapeutic doses.
As with any plasma-derived product, potential transmission of
blood-borne viruses was also of interest. The Registry was active
from 2010 to 2014; retrospective data from 2009 were also
captured through medical chart review. A planned 3-year interim
analysis was published previously, including data on 135 subjects
and 3196 pnfC1-INH infusions.21 The ﬁnal dataset reported
here is substantially larger, reﬂecting 15,000 pnfC1-INH in-
fusions in 318 subjects. In addition, criteria for deﬁning adverse
events (AEs) were reﬁned since the interim analysis such that
nonserious HAE attack signs and symptoms were no longer
classiﬁed as AEs, allowing for a more speciﬁc analysis of pnfC1-
INH safety and tolerability.
METHODS
Study design
This multicenter, observational, patient Registry
(NCT01108848) was conducted at 30 US and 7 European sites
(Germany, 5; Denmark, 1; Switzerland, 1). Procedures were con-
ducted in accordance with local regulatory requirements pertaining
to noninterventional studies; all subjects provided informed consent
for collection of treatment data. The study protocol and master
informed consent form were reviewed and approved by relevant
institutional review boards and independent ethics committees.
Data collection and analysis
The Registry enrolled individuals of any age using pnfC1-INH
(Berinert) for any reason. Both retrospective (infusion occurring
before enrollment) and prospective (infusion occurring after enroll-
ment) data on the use of pnfC1-INH were obtained. The following
data were collected: patient demographics; reason for pnfC1-INH
administration; pnfC1-INH dose; place of administration (health
care setting or outside of a health care setting); anatomic location
and severity of attacks; and AEs, including potential TEEs,
appearance of anti-C1-INH antibodies, and suspected viral trans-
mission. HAE attack data were collected only for attacks treated with
pnfC1-INH. Investigators were required to record the reason for
C1-INH infusion as acute treatment, prophylaxis, or other. Treat-
ment outside of a health care setting included any pnfC1-INH
infusion that was administered by the subject, a family member,
friend, or other caregiver in a non-health care setting. Treatment in a
health care setting included any pnfC1-INH infusion that was
administered by a health care professional (eg, a physician or nurse)
in a health care institution (eg, hospital or clinic).
TEEs were identiﬁed using the Medical Dictionary for Regu-
latory Activities (MedDRA), Standardized MedDRA Queries
(SMQ) for embolic and thrombotic events. A separate question-
naire was completed for suspected TEEs to obtain additional in-
formation. Monitoring of suspected viral transmissions was per
usual clinical practice; investigators were to test for viral trans-
mission based on their medical judgment and routine standard of
medical care. Prospectively, patients were queried about AEs ateach clinic visit; medical charts were reviewed for possible AEs
related to prospectively recorded infusions (administered before
enrollment). All AEs were recorded, regardless of suspected cau-
sality to pnfC1-INH administration. The collection period for AEs
reﬂected a 1-month period after each administration of pnfC1-
INH. Causality was evaluated by the investigator as either not
related, unlikely related, possibly related, probably related, or
related. The intensity of each AE was graded by the investigator as
mild (easily tolerated, no interference with daily activities), mod-
erate (causing some interference with daily activities), or severe
(incapacitating; inability to do work or perform usual activities).
Serious AEs (SAEs) were those resulting in death, life-threatening
circumstances, requiring hospitalization, or resulting in persistent
or signiﬁcant disability or incapacity. In this report, signs and
symptoms of HAE attacks, as reﬂective of the condition under
study, were not reported as AEs. The exception was for HAE at-
tacks that also met SAE criteria; these were dually reported as SAE
and HAE attacks. Of note, in the previously published interim
report, the overall number of AEs did include nonserious HAE
attacks.21 AEs were followed by the investigator until such time
that the AE was considered resolved or was deemed a permanent
condition.
AEs that were missing a reported intensity grading were conser-
vatively assumed to be “severe” and reported in data tables in both
the “severe” and “missing” categories. Events with missing causality
were categorized by convention as “related.” Data were summarized
using descriptive statistics. AE rates were plotted by dose, and the
coefﬁcient of correlation (R) was calculated.
RESULTS
Subjects
Of 343 patients who enrolled in the Registry, 318 received 1
or more doses of pnfC1-INH and comprised the safety popu-
lation for this analysis. Subjects were predominantly female
(65.1%) and white (93.7%) and ranged in age from 5 to 83 years
(Table I). A majority of subjects (n ¼ 213, 67.0%) used pnfC1-
INH for treatment of HAE attacks only, 13 subjects used pnfC1-
INH as prophylaxis only, and 92 subjects used pnfC1-INH for
both attack treatment and prophylaxis. Among subjects who
received pnfC1-INH exclusively in a non-health care setting,
TABLE II. HAE attack characteristics and corresponding mean
pnfC1-INH doses
Attacks,
n (%)
Subjects with
attacks, n (%)
pnfC1-INH dose
per attack (IU/kg)
Median (range)
Total 11,844 305 (95.9) 11.6 (3.4-37.8)
Anatomic location
of attack*
Abdominal 4839 (40.9) 239 (78.4) 12.2 (3.6-35.7)
Facial 349 (2.9) 123 (40.3) 14.6 (3.4-35.7)
Laryngeal 242 (2.0) 85 (27.9) 14.7 (4.0-37.8)
Peripheral 2742 (23.2) 166 (54.4) 9.7 (3.5-31.5)
Thoracic 347 (2.9) 56 (18.4) 10.4 (3.6-23.3)
Other (or multiple
locations)
1494 (12.6) 144 (47.2) 12.0 (3.5-32.3)
Unknown 1831 (15.5) 68 (22.3) e
Attack intensity†
Mild 3748 (31.6) 9 (3.0) 6.7 (3.5-32.6)
Moderate 4734 (40.0) 64 (21.0) 12.2 (3.4-32.3)
Severe 1764 (14.9) 228 (74.8) 14.1 (3.5-37.8)
Unknown 1598 (13.5) 4 (1.3) e
HAE, Hereditary angioedema; IU, international units; kg, kilograms; pnfC1-INH,
plasma-derived, highly puriﬁed, pasteurized, nanoﬁltered C1-inhibitor concentrate.
*For per subject reporting of anatomic location, the n value represents the number of
subjects who experienced 1 attack in the anatomic location.
†For per subject reporting of attack intensity, each subject is included in only 1
category based on the maximum intensity attack.
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American), and 0.6% were Asian.
HAE attack characteristics
The most frequent types of HAE attacks treated with pnfC1-
INH were abdominal (40.9%) and peripheral (23.2%), experi-
enced at least once by 78.4% and 54.4% of subjects, respectively
(Table II). Facial and laryngeal attacks were experienced by
40.3% and 27.9% of subjects, respectively. Most attacks
(40.0%) were moderate in intensity. However, 75% of subjects
experienced at least 1 severe attack.
pnfC1-INH infusions
The Registry captured data on a total of 15,000 pnfC1-INH
infusions (Figure 1, A), of which 11,848 (79.0%) were admin-
istered for on-demand treatment of HAE attacks, and 3142
(20.9%) were given for HAE prophylaxis (reason unknown for
10 infusions). The number of pnfC1-INH infusions per subject
varied considerably and ranged from 1 to 612. Of the 15,000
pnfC1-INH infusions, 5852 (39.0%) were administered before
(retrospective to) a subject’s Registry enrollment; these data were
gathered via a chart review after a subject’s enrollment into the
Registry. Data on 9148 (61.0%) infusions were collected on an
ongoing, prospective basis during the Registry period. The ma-
jority of pnfC1-INH infusions (70.7%) were documented in
European subjects (Figure 1, B). For European and US sites,
respectively, 53% and 19% of the reported infusions had been
retrospectively administered.
pnfC1-INH dosing patterns
Doses of pnfC1-INH per infusion ranged from 3.4 IU/kg to
37.8 IU/kg for on-demand treatment and from 3.6 IU/kg to
33.9 IU/kg for prophylaxis. As shown in Table III, the highestmedian doses were noted in the following patient categories:
youngest age groups, those receiving prophylactic treatment, US
subjects, and those with prospectively collected data. With
respect to attack characteristics, the highest median doses were
recorded for facial and laryngeal attacks and for severe attacks
(Table II).
Setting of pnfC1-INH administration
Administration of pnfC1-INH outside of a health care setting
was documented for 14,072 (95.0%) infusions in 224 (70.4%)
subjects. A total of 95.2% of attack treatment infusions and
94.1% of prophylactic infusions were administered outside of a
health care setting. Changes in the administration setting (non-
health care setting to health care setting) occurred 68 times in 29
(9.1%) subjects (Figure 2). “Failure to self-infuse” (inability to
ﬁnd a vein or IV port) was recorded in <0.1% of infusions (13
events in 6 subjects) administered outside of a health care setting,
almost all of which were involving treatment of attacks.
Safety
There were no AEs reported for infusions administered before
enrollment (retrospective infusion data; 39.0% of all infusions).
Because of this ﬁnding, only prospectively administered infusions
(9148 infusions) and individuals who contributed at least 1
prospective data point (n ¼ 296 subjects) were included in the
safety analysis. Among these subjects/infusions, 252 AEs were
noted in 85 (28.7%) subjects (Table IV), for an overall rate of
0.03 AEs per pnfC1-INH infusion and 0.85 AEs per subject.
The most commonly reported AEs (12.8% of subjects) were
infections (noneblood-borne viral infections; primarily respira-
tory tract related) and gastrointestinal disorders (5.7% of sub-
jects). Most AEs were mild (51.2%) or moderate (38.1%) in
intensity. The majority (96.4%) of AEs were considered unre-
lated to pnfC1-INH administration. Nine AEs occurring in 6
subjects were considered to be at least possibly related to pnfC1-
INH treatment, including headache (4 events in 3 subjects) and
1 event each of gastroesophageal reﬂux disease, hematoma,
noncardiac chest pain, and fatigue. One serious AE (deep vein
thrombosis) was considered at least possibly related to pnfC1-
INH; this patient had an indwelling central line (see additional
details on this case in a following paragraph). There were no
events of anaphylaxis or events suggestive of drug-related
hypersensitivity.
The AE rates per subject and per infusion were similar for
pnfC1-INH infusions given as prophylaxis (0.63 per subject,
0.03 per infusion) or for attack treatment (0.66 per subject, 0.03
per infusion). The overall AE rate per infusion was higher among
infusions given in a health care setting (0.13) compared with
those given in a nonehealth care setting (0.02). The rates of AEs
considered related to pnfC1-INH administration were very low
in both health care and non-health care settings (<0.005 events
per infusion).
One subject treated with pnfC1-INH at doses between 20
and 25 IU/kg had a disproportionate number of AEs (25 of 252
events, or 11% of all AEs reported). Sensitivity analysis
comparing dose and adverse events, excluding data from this
subject, conﬁrmed that there was no evidence of a dose rela-
tionship with AEs in prospective data (Figure 3).
Overall, 34 SAEs were reported in 14 subjects, all of whom
were 18 years of age or older. Of the 34 SAEs, 29 occurred after
infusions for attack treatment. The most common SAE was HAE
FIGURE 1. Number of pnfC1-INH infusions captured in the Registry, by nature of data collection (retrospective vs prospective) and A,
reason for infusion (not recorded for 10 infusions) or B, geographical location (US vs EU). EU, European Union; pnfC1-INH, plasma-
derived, highly purified, pasteurized, nanofiltered C1-inhibitor concentrate; US, United States.
FIGURE 2. Location of pnfC1-INH administration, health care setting vs outside of a health care setting, by indication for use. pnfC1-INH,
Plasma-derived, highly purified, pasteurized, nanofiltered C1-inhibitor concentrate.
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were generally regarded as a condition under study and not re-
ported as AEs unless they fulﬁlled criteria deﬁning an SAE, such
as hospitalization. The majority of HAE attacks requiring hos-
pitalization (9 of 15 attacks) occurred in a single subject. This
subject had a self-directed pattern of treatment typically char-
acterized by delays in treatment initiation of 24 to 48 hours after
onset of an HAE attack. In this study, 1 SAE (DVT, described
below) was considered to be related to pnfC1-INH treatment.
With the exception of 1 case of fatal myocardial infarction, also
described below, all SAEs resolved without sequelae.
There were 2 TEEs identiﬁed (deep vein thrombosis [DVT]
and myocardial infarction) among 296 subjects/9148 infusions
with prospective data, for a rate of 0.007 TEEs per subject and0.0002 TEEs per infusion. A 36-year-old female subject with
HAE with normal C1-inhibitor and an indwelling subclavian
venous access port experienced an upper extremity DVT, also
affecting the chest, which was graded as severe and considered
probably related to pnfC1-INH. This subject had been using
pnfC1-INH (intravenously) for long-term prophylaxis, and had
received pnfC1-INH 11 days before the event (500 IU), 7 days
before the event (1000 IU), 3 days before the event (2 doses of
500 IU), and the same day before the event (500 IU); she also
received a 500 IU dose after the event, on the same day, for
treatment of an attack. The port was removed and the event
resolved without sequelae. The second TEE was a fatal
myocardial infarction that occurred in a 57-year-old male subject
8 months after his last pnfC1-INH infusion. This subject had a
TABLE III. Median pnfC1-INH doses (IU/kg) by age, geographic
region, and data collection type (retrospective vs prospective)
Subjects
N
Infusions
N
pnfC1-INH
dose (IU/kg)
Median
pnfC1-INH
dose (IU/kg)
Range
Age group (y)
<12 18 275 15.6 6.0-35.7
12 to <17 21 521 14.7 5.6-30.1
17 to <65 252 12,503 12.5 3.4-37.8
65þ 27 1701 6.4 5.8-24.4
Reason for use*
HAE attack treatment 305 11,848 10.8 3.4-37.8
HAE prophylaxis 105 3142 16.6 3.6-33.9
Geographic region
US 156 4402 18.9 3.4-37.8
EU 162 10,598 9.1 3.5-35.7
Geographic region,
prospective data only
US 131 3559 19.5 3.4-37.8
EU 136 5589 9.7 3.5-34.0
Data collection type†
Retrospective 251 5852 10.0 3.6-35.7
Prospective 267 9148 13.0 3.4-37.8
HAE, Hereditary angioedema; EU, European Union; IU, international units; kg,
kilograms; pnfC1-INH, plasma-derived, highly puriﬁed, pasteurized, nanoﬁltered
C1-inhibitor concentrate; US, United States.
*Not known for 10 infusions.
†241 subjects had both retrospective and prospective data; 22 subjects had retro-
spective data only; 55 subjects had retrospective data only.
TABLE IV. Summary of safety findings (prospective data)
Subjects, n (%)
n [ 296* Events Rate/subject†
Rate/infusion
n [ 9148
infusionsz
Any AE 85 (28.7) 252 0.85 0.03
Related AEs 6 (2.0) 9 0.03 0.00
Serious AEsx 14 (4.7) 34 0.11 0.00
Discontinuation
secondary
to an AE
1 (0.3) 1jj 0.00 0.00
AE intensity,
n (%){
Mild 62 (20.9) 129 (51.2) 0.44 0.01
Moderate 33 (11.1) 96 (38.1) 0.32 0.01
Severe 16 (5.4) 27 (10.7) 0.09 0.00
AE, Adverse event; HAE, hereditary angioedema; SAE, serious adverse events.
*22 subjects (6.9%) had retrospective data only and are not included here; 5852
infusions (39%) were retrospectively collected and are not included here.
†Rate/subject calculated as the number of events divided by the number of subjects
who contributed  prospective data point (n ¼ 296).
zRate/infusion calculated as the number of events divided by the number of
prospective infusions (9148).
x15 SAEs were HAE attacks requiring hospitalization. See the text for more details.
jjThromboembolic event.
{If subjects had multiple events of the same intensity, they are counted only once.
Subjects could be counted in more than 1 category.
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968 RIEDL ETALcontributory history of severe coronary artery disease, hyperten-
sion, and hyperlipidemia. This event was considered unrelated to
pnfC1-INH.A third event of interest, although not matching any of
the embolic and thrombotic SMQ event terms, occurred in a
70-year-old female subject who experienced symptoms consistent
with a transient ischemic attack (TIA) occurring within
approximately 1 day after knee replacement surgery. Prophylactic
pnfC1-INH was administered the morning before and the
morning after the TIA-like event. The symptoms were consid-
ered to the result of a fat embolism secondary to the knee
replacement, and were considered unrelated to pnfC1-INH
therapy.
As the Registry was designed to document pnfC1-INH use
according to local standards of clinical care, routine viral testing
was not required, and testing was to be conducted only if a
clinician considered it necessary. In the Registry, there were no
reports of testing for blood-borne viral infection conducted on
any subject beyond baseline, and no subject was reported to have
an adverse experience reﬂective of new infection with a blood-
borne virus, including human immunodeﬁciency virus (HIV),
hepatitis B virus, hepatitis C virus, and parvovirus B19 during
participation in the Registry.DISCUSSION
The Berinert Patient Registry dataset represents the largest
known registry of Berinert use. The HAE attack characteristics
noted in this Registry were generally consistent with patterns
previously reported by other authors.22-26 Abdominal and pe-
ripheral attacks were most common; laryngeal attacks comprised
only 2% of all attacks reported in the Registry, but 28% of
subjects experienced at least 1 laryngeal attack.
Analysis of administration patterns revealed wide use of
pnfC1-INH for prophylaxis as recommended in recent clinical
guidelines,1,5-10 despite the absence of regulatory approval of
Berinert for this purpose in the United States. As reviewed by
Bork et al,27 a number of observational and descriptive (ie,
surveys and case reports) studies support the efﬁcacy of C1-INH
for short-term prophylaxis before a scheduled procedure. The
efﬁcacy of C1-INH for long-term prophylaxis has also been
demonstrated in several noneplacebo-controlled observational,
descriptive, or cohort studies.27-29
There was a wide variation of pnfC1-INH dosing in the
Registry. Although median pnfC1-INH doses were generally
close to the recommended 20 IU/kg, particularly in the United
States, there was a great deal of variability noted across the
Registry dataset. Recorded doses per single infusion ranged from
3.4 to 37.8 IU/kg, or 500 to 3500 IU. This may indicate a high
level of therapy individualization, as is being increasingly rec-
ommended among recent HAE consensus guidelines.5,6,9,10,14
Not surprisingly, median doses (by weight) were highest for
children, severe attacks, and laryngeal and facial attacks. Yet,
median doses for the most severe attacks were still lower than the
recommended dose of 20 IU/kg, likely inﬂuenced by lower
median doses represented in the European data. Stratiﬁcation of
subjects by age group revealed a pattern of age-related dosing,
with younger subjects receiving higher median doses by weight
than older subjects.
The highermedian dosages reported for prospective (13.0 IU/kg)
versus retrospective (10.0 IU/kg) infusions may reﬂect a trend
toward usage of the recommended weight-based dosages in
recent years, particularly in Europe. Dosing of Berinert in
Europe before 2009 was according to a ﬁxed-dose
FIGURE 3. Plot of adverse event (AE) rates by pnfC1-INH dose (prospective data only, excluding 1 subject with a disproportionate number
of AEs). AE rate calculated as the number of events at the dose divided by the number of infusions of the same dose. The size of each plot
symbol (circle) reflects the relative number of subjects with the specified dose. One subject treated with pnfC1-INH doses between 20
and 25 IU/kg had a disproportionate number of AEs (25 of 252 events, or 11% of all AEs reported). IU, International unit; kg, kilogram;
pnfC1-INH, plasma-derived, highly purified, pasteurized, nanofiltered C1-inhibitor concentrate.
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result in relatively lower doses by body weight in most adults. In
2009, dosing guidelines were changed to reﬂect weight-based
dosing consistent with results of a rigorous phase II/III
controlled dose-ranging clinical trial22 and subsequent US
labeling. As a result, retrospective data from Europe reﬂected
lower median doses of pnfC1-INH. However, differences in the
proportion of data collected retrospectively versus prospectively
do not explain the use of higher dosages in the United States,
because a clear difference was apparent even when comparing
only prospective data (median doses of 19.5 IU/kg in the United
States vs 9.7 IU/kg in Europe). It is possible that the lower doses
used in Europe reﬂect a carry-over from years of experience with
ﬁxed dosing of pnfC1-INH before the change in dosing
recommendations.
Recent HAE expert guidelines consistently recommend
training and equipping patients for self- or home-based admin-
istration of HAE medications,1,5,6,8-10,12,14 and the Registry
ﬁndings support the safety and feasibility of pnfC1-INH
administration outside of the health care setting. Approxi-
mately 95% of all infusions captured in the Registry were given
outside of a health care setting, whether used for attack treatment
or prophylaxis. There were very few instances of subjects having
difﬁculty with administration; failure to self-infuse (successfully
administer pnfC1-INH outside of a health care setting) occurred
in less than 1 of 1000 self-infusions. Prior reports have also
indicated a good safety record with administration of pnfC1-
INH outside of a health care setting.30,31 The overall rates of
AEs per infusion (0.03) and per subject (0.85) were very low,regardless of administration setting. The relatively higher AE
rates noted for infusions given within a health care setting (0.13
per infusion) versus outside of a health care setting (0.02 per
infusion) may be a phenomenon caused, in part, by subjects
presenting to health care facilities for treatment of more severe
attacks and/or subjects presenting to health care facilities for
treatment well after attack onset. It has been shown that delayed
treatment after onset of HAE attacks is associated with longer
time to symptom relief and full attack resolution, and with
higher severity of certain symptoms that can be regarded as
AEs.32,33 The rates of AEs considered related to pnfC1-INH
were the same for both types of treatment settings.
Data from the Registry support the overall safety of pnfC1-
INH. A very low AE rate (0.03 events per infusion, prospectively
collected data) was observed, regardless of reason for use, and there
was no apparent dose relationship. The overall number of AEs (252
events) was smaller than the number reported in the interim
analysis (299 events),21 which is a reﬂection of the revised reporting
of individual symptoms of HAE attacks (eg, pain, swelling) that
had been previously reported as AEs, to align with the Registry
protocol speciﬁcations. Attacks requiring hospitalization were
classiﬁed as SAEs in the current analysis. The majority of such
events (9 of 15) occurred in a single subject whose treatment was
often initiated well after the onset of the HAE attack.
Although there have been rare postmarketing reports of
anaphylactic reactions in patients using pnfC1-INH in Europe,34
there have been no such reports in clinical trials or in this large
patient Registry population, suggesting that the risk of systemic
hypersensitivity reactions appears to be extremely small.
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was not mandated. Per routine medical practice, physicians
would have tested patients only if viral infection was suspected,
and there were no recorded ﬁndings of posteRegistry enrollment
viral testing. The apparent lack of testing during subjects’ Reg-
istry participation suggests that there was little clinical reason to
conduct such testing. The absence of viral transmission during
pnfC1-INH therapy has been reported in other prospective
studies.22,35 Routine testing for viral transmission is not speciﬁed
in the Berinert or Cinryze prescribing information, nor in most
HAE consensus guidelines. However, the World Allergy Orga-
nization guidelines do suggest “annual assessment for infections
with hepatitis B, C, and HIV,” as well as vaccination for hepatitis
A and B.6
Rare reports of TEEs in patients treated with C1-INH products
have led to heightened surveillance regarding this phenomenon
and its possible relationship to C1-INH administration. Five such
cases, all with risk factors for TEE, were reported during an
open label HAE prophylaxis trial with the plasma-derived C1-
INH concentrate Cinryze (Shire ViroPharma, Lexington, Mass).
A report published in 200018 described thrombus formation in
13 neonates and babies who received very high doses of pnfC1-
INH/Berinert (up to 500 IU/kg) for the off-label purpose of
preventing capillary leak syndrome after cardiopulmonary
bypass surgery; 9 of the events were fatal. These children were
seriously ill and had multiple other risk factors for TEE, yet the
role of pnfC1-INH was considered at least “possible” and
ongoing surveillance of this issue has been prudent.
The Registry sought speciﬁcally to identify and evaluate re-
ports of TEE among individuals using pnfC1-INH. The
observed risk of TEE was extremely low. Two events occurred
among 9148 prospectively collected pnfC1-INH infusions; one
of these, in a subject with an indwelling port, was considered
related. Both subjects had pre-existing risk factors for TEE. A
review of the Food and Drug Administration’s Adverse Event
Reporting System database in 2011 noted rare reports of TEE in
patients using Cinryze at recommended doses; no assessments of
causality were available in those cases.20 In addition, an inter-
national survey of 37 physicians caring for 856 patients with
HAE reported 5 “abnormal clotting” events, 3 of which were
noted in patients with indwelling catheters.36 It should be noted
that the ofﬁcial product labeling for both Berinert and Cinryze
includes a precaution to closely monitor patients with known risk
factors for thromboembolic events.
This Registry has several limitations. There were no AEs re-
ported to the Registry for infusions given before enrollment
(retrospective), the identiﬁcation of which, during a chart review,
may have been hindered, at least in part, by the 30-day post-
infusion time window for identifying AEs as speciﬁed by the
Registry protocol. As a result, only prospective data were used for
AE rate calculations. Another limitation inherent to registry
studies is that data were limited by what was gathered by the
treating physician in the course of routine patient management.
Further, as is typical for an observational study, this registry did
not have a control group. Because the key requirement for
participation was exposure to at least 1 dose of Berinert and
because there was no mandatory duration of Registry participa-
tion for any subject, a wide range in the number of infusions per
subject was recorded, from 1 to several hundred. Such a range
could bias results with weighting toward those who contributed
greater amounts of information. However, the sheer volume of15,000 infusions captured for 318 patients with HAE in the
Registry over the 5-year period of time supports the clinical value
of these observations.
Subjects represented in the Registry comprised a diverse
population in terms of geography and age. Approximately two-
thirds of subjects were female, despite no known sex-related
differences in the prevalence of HAE types 1 and 237; this may
reﬂect a greater willingness among women to participate in this
voluntary registry. With regard to race, the Registry population
was quite homogenous, with approximately 94% of subjects
being white. Of particular interest are the ﬁndings that there
were very few black/African American subjects who used pnfC1-
INH for prophylaxis, or administered pnfC1-INH in a non-
health care setting. It is possible that the underrepresentation
of ethnic minorities in the Registry, overall and in speciﬁc cat-
egories, is related to disparities in access to care, and further
studies are needed to explore this possibility.CONCLUSIONS
This large patient Registry documents the international
implementation of pnfC1-INH self-administration outside of the
health care setting, as currently recommended by HAE consensus
guidelines. The data also indicate substantial use of pnfC1-INH
(Berinert) for HAE prophylaxis. There was no evidence of a dose
relationship for AEs, and few reported events were considered
related to treatment. There were no reported events of suspected
blood-borne viral infections; viral testing was not performed as a
routine measure in this real-world study. Thromboembolic
events were rare, and occurred in patients with pre-existing risk
factors, supporting current recommendations to closely monitor
patients with known risk factors. There were no reports of
anaphylaxis or events suggestive of systemic hypersensitivity
to Berinert. Overall, these real-world ﬁndings support the
safety of pnfC1-INH whether given within or outside of a health
care setting and as given for a variety of reasons in patients with
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